Avadel Pharmaceuticals Company Leadership
| AVDL Stock | USD 11.06 0.11 0.98% |
Avadel Pharmaceuticals employs about 154 people. The company is managed by 12 executives with a total tenure of roughly 5 years, averaging almost 0.0 years of service per executive, having 12.83 employees per reported executive. Inspection of Avadel Pharmaceuticals' management performance can provide insight into the company performance.
| Gregory Divis President Executive Vice President Chief Commercial Officer |
Avadel Pharmaceuticals' Insider Buying Vs Selling
50
Selling | Buying |
Latest Trades
| 2024-01-16 | Thomas S Mchugh | Acquired 2000 @ 14.5 | View | ||
| 2023-12-28 | Mark Anthony Mccamish | Disposed 75000 @ 14.53 | View |
Monitoring Avadel Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Avadel |
Avadel Pharmaceuticals' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Avadel Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Avadel will maintain a workforce of about 150 employees by January 2025.Avadel Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.3445) % which means that it has lost $0.3445 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9952) %, meaning that it created substantial loss on money invested by shareholders. Avadel Pharmaceuticals' management efficiency ratios could be used to measure how well Avadel Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is expected to rise to -1.03 this year. Return On Capital Employed is expected to rise to -1.02 this year. At this time, Avadel Pharmaceuticals' Non Current Assets Total are quite stable compared to the past year. Fixed Asset Turnover is expected to rise to 8.17 this year, although the value of Total Assets will most likely fall to about 134.2 M.Common Stock Shares Outstanding is expected to rise to about 84.2 M this year, although the value of Net Loss is projected to rise to (117.5 M).
Avadel Pharmaceuticals Workforce Comparison
Avadel Pharmaceuticals PLC is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 15,028. Avadel Pharmaceuticals claims roughly 154 in number of employees contributing just under 2% to equities under Health Care industry.
Avadel Pharmaceuticals Profit Margins
The company has Profit Margin (PM) of (1.12) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.31) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.31.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.65 | 0.87 |
|
|
Avadel Pharmaceuticals Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Avadel Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Avadel Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Avadel Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-09-01 | 6.0 | 12 | 2 | 132,000 | 22,000 |
| 2024-06-01 | 0.1429 | 1 | 7 | 49,500 | 407,500 |
| 2023-09-01 | 2.6667 | 8 | 3 | 191,000 | 94,975 |
| 2022-09-01 | 7.0 | 7 | 1 | 294,000 | 42,000 |
| 2021-09-01 | 5.0 | 5 | 1 | 210,000 | 42,000 |
| 2020-12-01 | 4.0 | 4 | 1 | 802,000 | 18,600 |
| 2019-12-01 | 9.0 | 9 | 1 | 526,500 | 3,072 |
| 2018-09-01 | 4.0 | 8 | 2 | 248,010 | 22,587 |
| 2018-06-01 | 5.0 | 5 | 1 | 33,467 | 114,034 |
| 2017-12-01 | 17.0 | 17 | 1 | 866,300 | 254,265 |
| 2017-06-01 | 6.3333 | 19 | 3 | 392,500 | 287,560 |
| 2017-03-01 | 22.0 | 154 | 7 | 11,196,678 | 4,604,464 |
| 2016-12-01 | 0.7258 | 45 | 62 | 2,121,100 | 3,920,377 |
| 2016-09-01 | 5.5 | 11 | 2 | 177,000 | 115,000 |
| 2016-06-01 | 0.6 | 3 | 5 | 32,228 | 304,527 |
| 2016-03-01 | 0.1786 | 5 | 28 | 128,000 | 1,808,000 |
| 2003-09-01 | 3.0 | 6 | 2 | 2,850,000 | 1,011,704 |
Avadel Pharmaceuticals Notable Stakeholders
An Avadel Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Avadel Pharmaceuticals often face trade-offs trying to please all of them. Avadel Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Avadel Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Gregory Divis | Executive Vice President Chief Commercial Officer | Profile | |
| Gregory Davis | VP Development | Profile | |
| Thomas McHugh | Principal VP | Profile | |
| Richard Kim | Chief Officer | Profile | |
| Christian PharmD | Chief Affairs | Profile | |
| Steven Sullivan | VP Operations | Profile | |
| Jason Vaughn | Senior Operations | Profile | |
| Jennifer PharmD | Senior Affairs | Profile | |
| Mark Elrod | Vice Sales | Profile | |
| Jordan MD | Consultant | Profile | |
| Angie Woods | Vice Culture | Profile | |
| Jerad Seurer | General Secretary | Profile |
About Avadel Pharmaceuticals Management Performance
The success or failure of an entity such as Avadel Pharmaceuticals often depends on how effective the management is. Avadel Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Avadel management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Avadel management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.08) | (1.03) | |
| Return On Capital Employed | (1.08) | (1.02) | |
| Return On Assets | (0.97) | (0.92) | |
| Return On Equity | (1.83) | (1.92) |
Avadel Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Avadel Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Avadel Pharmaceuticals within its industry.Avadel Pharmaceuticals Manpower Efficiency
Return on Avadel Pharmaceuticals Manpower
| Revenue Per Employee | 181.6K | |
| Revenue Per Executive | 2.3M | |
| Net Loss Per Employee | 1M | |
| Net Loss Per Executive | 13.4M | |
| Working Capital Per Employee | 632.1K | |
| Working Capital Per Executive | 8.1M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avadel Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avadel Pharmaceuticals. If investors know Avadel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avadel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.09) | Revenue Per Share 1.036 | Quarterly Revenue Growth 26.743 | Return On Assets (0.34) | Return On Equity (1.00) |
The market value of Avadel Pharmaceuticals is measured differently than its book value, which is the value of Avadel that is recorded on the company's balance sheet. Investors also form their own opinion of Avadel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Avadel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avadel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Avadel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avadel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avadel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avadel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.